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natomical Suitability for
ranscatheter Aortic Valve
mplantation With
omplementary Roles
or 2 Rivals*
eter Wenaweser, MD, Stephan Windecker, MD
ern, Switzerland
he study of Jilaihawi et al. (1) investigates the anatomic
uitability of present- and future-generation transcatheter aor-
ic valve prostheses. The principal finding is that 97% of
atients screened for transcatheter aortic valve implantation
TAVI) are eligible for treatment with either the Edwards
apien valve (ESV) (Edwards Lifesciences, Irvine, California)
r the Medtronic CoreValve Revalving System (MCRS)
Minneapolis, Minnesota) with evidence of complementary
tility. The investigators screened 100 patients with angiogra-
hy, transthoracic or transesophageal echocardiography, as well
s computed tomography with 3-dimensional reconstruction
or technical feasibility. The focus of the assessment was on:
) diameter of the common femoral artery; 2) diameter of the
ative valve annulus; and 3) dimension of the ascending aorta.
See page 859
Transcatheter aortic valve implantation for the treatment
f severe aortic stenosis in patients at high risk for surgery
as already been performed in more than 20,000 patients
orldwide since its first clinical application in 2004 (2).
ith growing experience, it has become evident that the
creening process represents an integral component for the
uccessful implementation of TAVI. However, evaluation
f technical feasibility is only but 1 important consideration
uring the screening process. Careful assessment of risk for
onventional surgical aortic valve replacement, identification
f comorbidities, geriatric assessment, evaluation of frailty,
nd an interdisciplinary discussion of various therapeutic
ptions should precede evaluation of technical feasibility (3).
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the Department of Cardiology, Bern University Hospital, Bern, Switzerland.b
rs. Wenaweser and Windecker receive honoraria and lecture fees from Medtronic
oreValve and Edwards Lifesciences.A technical limitation of the current CE-approved devices
or the transfemoral approach is the diameter of the common
emoral artery (CFA). At least 6 mm for the MCRS and 7 to
mm for the ESV are required for the introduction of an 18-F
r 22-/24-F sheath, respectively. The diameter of the CFA
epends on age, sex, and body surface area and ranges between
and 10 mm in healthy subjects (4). Typically, female patients
f small stature with severe aortic stenosis have small CFA not
xceeding 6 mm in diameter. Of note, the minimal required
iameter is feasible for patients with only mild tortuosity and
bsence of calcification of the iliofemoral axis. For patients
ith either peripheral vascular disease, which is present to
ome degree in most patients cases screened for TAVI (5), or
enal insufficiency, at least 7 mm for the MCRS or 8 to 9 mm
or the ESV system are required in order to overcome the
riction imposed by the calcified and stiff vasculature. Periph-
ral vascular disease substantially influences the technical fea-
ibility of the transfemoral approach as calcified parts of the
FA increase the risk of access site complications including
issections and perforations, especially if choosing a pure
ercutaneous approach with a closure device. Early experience
hows that vascular access site complications and associated
leeding events are the most frequently encountered problems
uring TAVI (6–10). As bleeding is associated with adverse
linical outcome, meticulous screening of the intended access
ite remains of paramount importance. As bailout or alternative
ption, a surgical cutdown of the external iliac artery, a
ransapical approach, or a trans-subclavian access have to be
onsidered.
Along with the diameter of the CFA goes the diameter of
he native aortic valve. Anatomic studies highlight that the
ange of the aortic annulus diameter lies between 18 and 29
m. Whereas the MCRS currently covers the range of 20
o 27 mm, the ESV can be used for a range between 18 and
5 mm. Accordingly, only a minority of patients with very
mall or exceedingly large anatomy are not amenable to
reatment with either of the 2 devices as highlighted by
ilaihawi et al. (1). These net figures, however, obscure the
act that the aortic valve annulus has an elliptical rather than
ound shape and that the optimal tool for measuring the
imensions of the valve for the clinical setting of TAVI
emain to be determined. Computed tomography scan
easurements in the coronal view tend to overestimate the
iameter, whereas reconstruction in the sagittal view often
nderestimates the diameter due to the septal muscular
ulge. Transthoracic echocardiography can reliably exclude
too small annulus, whereas transesophageal echocardiog-
aphy, which is frequently used due to its superior image
uality, exposes only 1 dimension in the long-axis view.
easurements of invasive aortography correlate well with
he coronal view of the computed tomography scan and
herefore tend to overestimate the true annular dimensions.
inally, direct measurement of the valve plane during
alloon dilation with simultaneous dye injection into the
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868ortic root can be considered for cases with borderline
imensions. The pros and cons of the different measure-
ent tools are summarized in Tables 1 and 2. The role of
agnetic resonance imaging for measurement of the aortic
imensions remains to be elucidated (Fig. 1). Magnetic
esonance imaging may provide complete assessment of
ther valvular pathologies than aortic stenosis, provides
dditional information in terms of left and right ventricular
unction as well as myocardial viability, and is able to assess
emodynamic parameters. The lack of visualization of
alcified structures and the need of electrocardiogram trig-
ering remain, however, unresolved issues.
Beyond the annular dimensions, the distance of the
akeoff of the coronary arteries, the amount of calcification,
nd the diameter of the sinus portion are equally important
onsiderations when choosing between the 2 currently
vailable devices. Although coronary occlusion or myocar-
ial infarction is a rare complication, acute myocardial
schemia can be deleterious in this setting. For the ESV, a
inimal distance of 10 mm from the annular level to the
akeoff of the coronary arteries is recommended as the
eight of the valve amounts to 14 to 17 mm with the lower
alf being circumferentially covered to avoid paravalvular
eaks. Conversely, the frame of the MCRS circumvents the
isk of coronary occlusion as the mid-portion is constrained
Table 1. Tools for Measuring the Diameter of Aortic Valves
Annulus Diameter Image Quality Interobserver Variability
CT coronal  
CA  
TTE  
CT sagittal  
TEE  CT coronal
 TTE
— 
 for interobserver variability means high variability.
CA contrast aortography; CT computed tomography; TEE transesophageal echocardi-
ography; TTE transthoracic echocardiography.
Table 2. Advantages and Disadvantages of the Different Measurement Too
Pros
CT coronal Excludes too-large annulus
Measurement distance annulus to left main, RCA
CA No additional exam
Immediate result
TTE Immediate result
Excludes too-small annulus
CT sagittal Measurement distance annulus to left main, RCA
TEE High image qualityRCA right coronary artery; other abbreviations as in Table 1.nd leaves more space between the frame and the takeoff of
he coronary arteries. In case of a small sinus portion (30
m) of the aorta, however, occlusion of the coronary
rteries is still possible especially in case of a too high
mplantation of the MCRS prosthesis.
As the ascending aorta is usually not dilated in patients
ith degenerative aortic valve stenosis, the size of the
scending aorta usually does not exceed 45 mm. Dimensions
eyond 45 mm are formally considered to be an indication
or replacement of the ascending aorta and represent a
elative contraindication for the use of the MCRS as the
pper part of the frame helps to orient the valve plane.
The 2 currently available devices have important differences
n design. The ESV is a balloon-expandable system based on a
obalt-chromium stent that uses bovine pericardial tissue
Cons
Radiation, contrast, time-consuming, costs
No standardized projection
Image quality
Tends to underestimate the diameter of annulus (septal bulge)
Radiation, contrast, time-consuming, costs
Patients discomfort
Only 1 view
Heavy calciﬁcation may impair precise measurement
Figure 1. Aortic Stenosis Assessed by MRI
Aortic stenosis assessed by magnetic resonance imaging (MRI) (short-axis
view).ls
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869pecifically treated using an anticalcification process. The valve
equires correct deployment upon balloon inflation, as there is
o possibility to reposition or retrieve the device once ex-
anded. Coronary occlusion might occur due to shift of
alcified material toward the left main ostium. Notwithstand-
ng, these complications are exceedingly rare in experienced
ands. As the stent is small in height, no interference with the
eft ventricular outflow tract and the superficially located left
undle is to be expected. Therefore, the rate of complete
trioventricular-block or atrioventricular-conduction disorders
s low and comparable to conventional surgical aortic valve
eplacement. So far, a 22-/24-F sheath was used for the
ransfemoral approach. More recently, the NovaFlex system
Edwards Lifesciences) has been introduced with further
ownsizing of the sheath to 18-/19-F. This change in design
as considerably reduced the proportion of patients ineligible
or the transfemoral ESV system from 72% to 22% as men-
ioned by Jilaihawi et al. (1), challenging the previous advan-
age of the MCRS device in terms of vascular access and
imiting the eligibility differences between the 2 devices to
atients with large annuli (25 mm) and coronary ostia in
ery close proximity to the valve plane.
The MCRS device is based on a Nitinol frame and uses
orcine pericardium. This self-expanding system measures 5.5
m in height, provides strong radial force in the distal third of
he frame, which serves to anchor the device and is designed to
void contact of the frame with the coronary ostia. The device
ypically extends to the subvalvular septum with the incumbent
isk of interference with the left bundle branch (5). Conse-
uently, a higher rate of atrioventricular-conduction distur-
ances is noted (11). Conversely, the self-expanding frame
llows interventional cardiologists to correct the position of the
alve during deployment and even offers the possibility of
omplete retrieval as long as it is attached to the proximal
atheter tip. With respect to paravalvular leakage, no data have
irectly compared the 2 devices at this time. In light of the
lliptical shape of the native annulus, mild paravalvular regurgita-
ion is accepted but a potential impact on long-term clinical
utcome needs to be determined.
Although the current CE-approved devices cover up to
7% with respect to the anatomic measurements, future
evices will attempt to address the shortcomings of these
ystems. The following modifications will further expand
he anatomic suitability for transfemoral TAVI while re-
ucing the risk of periprocedural complications: 1) down-
izing of the introducer sheath in order to further reduce the
isk of vascular access complications; 2) development of a
implified and reproducible evaluation technique for the mea-
urement of the anatomic valve dimensions, the aortic root,
nd the peripheral arteries; 3) development of completely
epositionable and retrievable devices in order to immedi-
tely correct malpositioning and reduce paravalvular regur-
itation; 4) percutaneous closure systems with reliable per- aormance and ability to introduce a new device in case of
nsufficient access site closure.
In summary, the 2 current CE-approved devices are
omplementary and already cover a wide array of anatomic
imensions using various access routes today. The vast
ajority of TAVI procedures can be performed using the
ransfemoral approach, a trend that will be further enhanced
y continued efforts to downsize future devices. Under ideal
ircumstances, centers are in the position to choose between
he 2 currently approved devices according to the anatomic
onsiderations discussed herein to fully exploit the advan-
ages of TAVI in any given patient.
eprint requests and correspondence: Dr. Stephan Windecker,
rofessor and Head of Cardiology, Department of Cardiology,
ern University Hospital, 3010 Bern, Switzerland. E-mail:
tephan.windecker@insel.ch.
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